Question for the Docs and Smarts: Since the FDA knew how safe LL was a year ago (based on all the HIV patient data), how come - in our trial design - the FDA 1. did not let us start with an IV of LL and 2. limited the total dosage to two shots?
I'm not looking for a conspiracy, but if the drug is so incredibly safe - and knowing how much quicker it can help when administered as an IV - what was the medical rationale for these 2 decisions?
Is it not like a running a 100 yard dash with ankle weights?
Market Data 
Markets 
AI
